LONDON, Dec 10 () - Roche said on Wednesday its experimental oral drug giredestrant reduced the risk of breast cancer recurrence by ​30% compared with standard endocrine therapy, in what it said marked ‌the first big advance in hormonal treatment for the disease in over 20 years. The Swiss ‌drugmaker said detailed results from the phase III lidERA trial showed at three years, 92.

For espresso lovers, finding the ideal cup is a great excursion of flavors, fragrances, and fermenting procedures. The following are seven

Hollywood's most eclectic awards show will recognize the year's best in film, television and even podcasts on Jan. 11.